API Data Insights

In Focus

View All

The $245 Discount: Medicare Pays Up to 17× India’s Price for the Same Weight-Loss Molecule – and Calls It a Bargain

700,000 seniors, one flat copay, one net price agreed behind closed doors. Medicare's GLP-1 Bridge is being sold as the…

admin September 28, 2026September 28, 2026

Regulatory

The Annex III Club: Why September 29 Is the Real Deadline in Pharma’s Tariff War

admin September 21, 2026September 21, 2026

Market Watch Opinion

Antibiotic OPEC: The Shadow Cartels Monetizing the Ruins of the Strait of Hormuz

admin April 17, 2026April 17, 2026

Market Watch Signals

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

admin March 4, 2026March 4, 2026

Market Watch

Stop Searching, Start Connecting: Your Global API & FDF Hub

admin February 20, 2026February 20, 2026

Newswire

FDA’s Center for Drug Evaluation and Research Releases Updated Organization Chart

The FDA has published an updated organization chart for its Center for Drug Evaluation and Research (CDER), outlining key leadership roles within the agency. This comprehensive chart is crucial for industry stakeholders as it delineates the structure of CDER, which plays a vital role in the regulation of pharmaceuticals in the United States. Understanding the […]

October 5, 2026

Newswire

Sling ropes in $123m for oral thyroid eye disease drug

Sling has secured $123 million in funding to accelerate the development of its oral thyroid eye disease drug, positioning itself as a potential competitor to Amgen’s Tepezza, the current market leader. This significant investment underscores the growing interest in innovative treatments for thyroid eye disease, a condition that affects many patients and has seen limited […]

October 5, 2026

Newswire

AZ, Daiichi’s Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu has received a positive cost-effectiveness assessment from the National Institute for Health and Care Excellence (NICE) for use in treating HER2-low advanced breast cancer. This decision comes after a previous rejection in 2024, marking a significant turnaround for the drug’s market access in England and Wales. The NICE […]

October 5, 2026

Newswire

Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

The Danish drugmaker Novo Nordisk has announced its collaboration with Anthropic to leverage the AI model Claude Science, aiming to enhance its drug development processes. This strategic partnership underscores Novo’s ambition to position itself as the leading AI-driven healthcare company globally. As the pharmaceutical industry increasingly embraces artificial intelligence, Novo’s initiative reflects a broader trend […]

October 5, 2026

Newswire

Stanford Scientists Create Neuro-Chimeric Mice with Human Brain Organoids

Researchers at Stanford University have developed a groundbreaking method to grow human cerebral organoids within genetically modified mice that have had significant portions of their own brains removed. This innovative approach enhances the study of brain development and disease by allowing scientists to observe human brain cells in a living organism, a significant advancement in […]

October 5, 2026

Recently Featured

AI Failures Cost Life Sciences Organizations Millions as Process Gaps Persist

October 5, 2026

Artificial Intelligence adoption is accelerating across the healthcare and life sciences sectors, but poorly designed processes are emerging as a major obstacle to successful implementation, new research from Camunda suggests. The enterprise orchestration company’s latest report found that 66% of healthcare and life sciences organizations have experienced an AI initiative fail because of process-related challenges.…

MHRA Introduces Pre-Submission Service for Innovative Medicines

October 4, 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a pre-submission service aimed at supporting companies before they apply for Marketing Authorisations and clinical variations for innovative medicines. This initiative is designed to streamline the regulatory process, providing early guidance to pharmaceutical companies on their submissions. In the context of increasing competition and the…

Cellares Partners with GenomeFrontier to Evaluate Automation for Virus-Free CAR-T Production

October 4, 2026

Cellares has announced a strategic partnership with Taiwanese biotech firm GenomeFrontier Therapeutics to assess the efficacy of its cell shuttle platform in the production of virus-free CAR-T therapies. This collaboration marks a significant step in the ongoing evolution of CAR-T cell therapy manufacturing, particularly in addressing safety concerns associated with viral contaminants. The integration of…

Trialynx Wins DPHARM Idol Disrupt 2026

October 4, 2026

Trialynx has been awarded the prestigious DPHARM Idol Disrupt award at the 2026 DPHARM conference, a recognition that underscores its innovative contributions to the clinical trial landscape. This accolade highlights the company’s commitment to advancing trial methodologies and enhancing patient engagement through technology-driven solutions. As the pharmaceutical industry increasingly seeks to streamline processes and improve…

Ongoing Cases

Opinion Signals

The $245 Discount: Medicare Pays Up to 17× India’s Price for the Same Weight-Loss Molecule – and Calls It a Bargain

September 28, 2026September 28, 2026

700,000 seniors, one flat copay, one net price agreed behind closed doors. Medicare’s GLP-1 Bridge…

Regulatory

The Annex III Club: Why September 29 Is the Real Deadline in Pharma’s Tariff War

September 21, 2026September 21, 2026

Seventeen companies were named first when Washington imposed a 100% tariff on patented drugs and…

Market Watch Opinion

Antibiotic OPEC: The Shadow Cartels Monetizing the Ruins of the Strait of Hormuz

April 17, 2026April 17, 2026

In the last fourteen days, the cost of keeping a feverish child stable in a…

Market Watch Signals

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

March 4, 2026March 4, 2026

The biotech markets of early 2026 have become a theater of the extreme, where the…

Market Watch

Stop Searching, Start Connecting: Your Global API & FDF Hub

February 20, 2026February 20, 2026

If you’ve been in the pharma business for a while, you know that finding a…

Market Watch Signals

Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction

December 11, 2025December 11, 2025

The pharmaceutical sector has officially transitioned from cautious capital preservation to a state of aggressive,…

Market Watch Signals

Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch

October 14, 2025October 15, 2025

CRL Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch No fireworks. A 7:12…

Case Files Signals

Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours

October 10, 2025October 10, 2025

At 9:15 a.m. Mumbai time, Nov. 6, 2015, a single document changed billions in market…

Deep Dives Regulatory

Regulatory Pressure & Supply Shock: Why Europe’s Drug Shortages Became Chronic – and What Everyone’s Missing

September 20, 2025September 20, 2025

“Shortages aren’t accidents; they’re features of how the market is built.” Outside declared emergencies EMA…

Signals

Nitrosamines 2.0: new AI thresholds, new “casualties,” and finally predictable rules

September 10, 2025September 10, 2025

The story really does begin in a hot stretch of 2025, when three regulators –…

In Focus

The $245 Discount: Medicare Pays Up to 17× India’s Price for the Same Weight-Loss Molecule – and Calls It a Bargain

The Annex III Club: Why September 29 Is the Real Deadline in Pharma’s Tariff War

Antibiotic OPEC: The Shadow Cartels Monetizing the Ruins of the Strait of Hormuz

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

Stop Searching, Start Connecting: Your Global API & FDF Hub

FDA’s Center for Drug Evaluation and Research Releases Updated Organization Chart

Sling ropes in $123m for oral thyroid eye disease drug

AZ, Daiichi’s Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

Stanford Scientists Create Neuro-Chimeric Mice with Human Brain Organoids

AI Failures Cost Life Sciences Organizations Millions as Process Gaps Persist

MHRA Introduces Pre-Submission Service for Innovative Medicines

Cellares Partners with GenomeFrontier to Evaluate Automation for Virus-Free CAR-T Production

Trialynx Wins DPHARM Idol Disrupt 2026

Ongoing Cases

The $245 Discount: Medicare Pays Up to 17× India’s Price for the Same Weight-Loss Molecule – and Calls It a Bargain

The Annex III Club: Why September 29 Is the Real Deadline in Pharma’s Tariff War

Antibiotic OPEC: The Shadow Cartels Monetizing the Ruins of the Strait of Hormuz

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

Stop Searching, Start Connecting: Your Global API & FDF Hub

Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction

Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch

Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours

Regulatory Pressure & Supply Shock: Why Europe’s Drug Shortages Became Chronic – and What Everyone’s Missing

Nitrosamines 2.0: new AI thresholds, new “casualties,” and finally predictable rules

About Us

Contact & Support

Connect